About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5526972
Allelic
Composition
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-PIK3CA*H1047R,-luc)2239Jjz/0
Genetic
Background
involves: FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• females treated with doxycycline for 4 weeks exhibit increased mammary ductal side-branching and enlarged focal nodular structures filled with hyperproliferative cells characteristic of early neoplastic lesions
• chronic doxycycline induction results in development of mammary tumors with 95% penetrance and a mean latency of 7 months
• withdrawal of doxycycline from females bearing tumors results in tumor regression during the first week after doxycycline removal, with a reduction in cellular proliferation and increase in apoptosis
• withdrawal of doxycycline from females bearing tumors for up to 6 months results in 33% of tumors showing complete regression to a nonpalpable state within 1-2 months after doxycycline withdrawal with no regrowth, while 64% of tumors partially regress but then resume growth without doxycline and 3% partially regress but do not resume growth
• mammary tumors of doxycycline treated females include adenocarcinomas and adenosquamous carcinomas

integument
• females treated with doxycycline for 4 weeks exhibit increased mammary ductal side-branching and enlarged focal nodular structures filled with hyperproliferative cells characteristic of early neoplastic lesions
• chronic doxycycline induction results in development of mammary tumors with 95% penetrance and a mean latency of 7 months
• withdrawal of doxycycline from females bearing tumors results in tumor regression during the first week after doxycycline removal, with a reduction in cellular proliferation and increase in apoptosis
• withdrawal of doxycycline from females bearing tumors for up to 6 months results in 33% of tumors showing complete regression to a nonpalpable state within 1-2 months after doxycycline withdrawal with no regrowth, while 64% of tumors partially regress but then resume growth without doxycline and 3% partially regress but do not resume growth
• mammary tumors of doxycycline treated females include adenocarcinomas and adenosquamous carcinomas

neoplasm
• females treated with doxycycline for 4 weeks exhibit increased mammary ductal side-branching and enlarged focal nodular structures filled with hyperproliferative cells characteristic of early neoplastic lesions
• chronic doxycycline induction results in development of mammary tumors with 95% penetrance and a mean latency of 7 months
• withdrawal of doxycycline from females bearing tumors results in tumor regression during the first week after doxycycline removal, with a reduction in cellular proliferation and increase in apoptosis
• withdrawal of doxycycline from females bearing tumors for up to 6 months results in 33% of tumors showing complete regression to a nonpalpable state within 1-2 months after doxycycline withdrawal with no regrowth, while 64% of tumors partially regress but then resume growth without doxycline and 3% partially regress but do not resume growth
• mammary tumors of doxycycline treated females include adenocarcinomas and adenosquamous carcinomas

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
breast cancer DOID:1612 OMIM:114480
J:175839


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/23/2021
MGI 6.16
The Jackson Laboratory